JP5971769B2 - アントラサイクリン療法を用いて乳癌を処置する方法 - Google Patents

アントラサイクリン療法を用いて乳癌を処置する方法 Download PDF

Info

Publication number
JP5971769B2
JP5971769B2 JP2013558177A JP2013558177A JP5971769B2 JP 5971769 B2 JP5971769 B2 JP 5971769B2 JP 2013558177 A JP2013558177 A JP 2013558177A JP 2013558177 A JP2013558177 A JP 2013558177A JP 5971769 B2 JP5971769 B2 JP 5971769B2
Authority
JP
Japan
Prior art keywords
subtype
breast cancer
her2
biological sample
anthracycline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013558177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514278A5 (enExample
JP2014514278A (ja
Inventor
チャールズ エム． ペロウ，
チャールズ エム． ペロウ，
マシュー ジェイ． エリス，
マシュー ジェイ． エリス，
フィリップ エス． バーナード，
フィリップ エス． バーナード，
トルステン オー． ニールセン，
トルステン オー． ニールセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St. Louis
Original Assignee
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St. Louis filed Critical Washington University in St. Louis
Publication of JP2014514278A publication Critical patent/JP2014514278A/ja
Publication of JP2014514278A5 publication Critical patent/JP2014514278A5/ja
Application granted granted Critical
Publication of JP5971769B2 publication Critical patent/JP5971769B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
JP2013558177A 2011-03-15 2012-03-15 アントラサイクリン療法を用いて乳癌を処置する方法 Expired - Fee Related JP5971769B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453035P 2011-03-15 2011-03-15
US61/453,035 2011-03-15
PCT/US2012/029226 WO2012125828A2 (en) 2011-03-15 2012-03-15 Methods of treating breast cancer with anthracycline therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016075592A Division JP2016130256A (ja) 2011-03-15 2016-04-05 アントラサイクリン療法を用いて乳癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2014514278A JP2014514278A (ja) 2014-06-19
JP2014514278A5 JP2014514278A5 (enExample) 2015-03-19
JP5971769B2 true JP5971769B2 (ja) 2016-08-17

Family

ID=46831350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013558177A Expired - Fee Related JP5971769B2 (ja) 2011-03-15 2012-03-15 アントラサイクリン療法を用いて乳癌を処置する方法
JP2016075592A Pending JP2016130256A (ja) 2011-03-15 2016-04-05 アントラサイクリン療法を用いて乳癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016075592A Pending JP2016130256A (ja) 2011-03-15 2016-04-05 アントラサイクリン療法を用いて乳癌を処置する方法

Country Status (7)

Country Link
US (2) US9066963B2 (enExample)
EP (1) EP2685988A4 (enExample)
JP (2) JP5971769B2 (enExample)
AU (2) AU2012229123B2 (enExample)
CA (1) CA2830240A1 (enExample)
IL (1) IL228449A (enExample)
WO (1) WO2012125828A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
US9517229B2 (en) 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112015018929B8 (pt) * 2013-02-06 2023-01-31 Geissler Companies Llc Sistema de saúde eletrônico para determinar a eficácia de uma droga administrada usando análise de auscultação
EP3524698A1 (en) * 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the prognosis and treatment of cancer metastasis
AU2015349870B2 (en) 2014-11-21 2019-09-26 Bruker Spatial Biology, Inc. Enzyme- and amplification-free sequencing
ES2756399T3 (es) 2014-11-24 2020-04-27 Nanostring Technologies Inc Métodos y aparatos para la purificación y formación de imágenes de genes
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
CN114350752B (zh) 2015-07-17 2025-02-25 布鲁克空间生物学公司 在横切面组织的用户定义区域中的基因表达的同时定量
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CN116200462B (zh) 2016-05-16 2025-10-03 布鲁克空间生物学公司 用于检测样品中目标核酸的方法
CA3025264A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2017361521B2 (en) 2016-11-21 2020-08-27 Bruker Spatial Biology, Inc. Chemical compositions and methods of using same
CA3064564C (en) 2017-06-22 2021-11-30 SNBioScience Inc. Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR102893736B1 (ko) 2018-05-14 2025-11-28 브루커 스페이셜 바이올로지, 인크. 화학 조성물 및 이의 사용 방법
CN111455055B (zh) * 2020-04-28 2021-11-16 重庆浦洛通基因医学研究院有限公司 一种人类tyms基因表达量检测标准对照品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US20080032293A1 (en) 2004-07-15 2008-02-07 The University Of North Carolina At Chapel Hill Housekeeping Genes And Methods For Identifying Same
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
CA2635215C (en) 2005-12-23 2016-08-30 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
WO2007076129A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
EP2155899A2 (en) 2007-04-10 2010-02-24 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
SI2297359T1 (sl) * 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
JP5836803B2 (ja) 2008-08-14 2015-12-24 ナノストリング テクノロジーズ， インコーポレイテッド 安定したナノレポーター
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2874492C (en) 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
JP2015530072A (ja) 2012-06-29 2015-10-15 ナノストリング テクノロジーズ，インコーポレイティド ゲムシタビン療法による乳癌の治療方法

Also Published As

Publication number Publication date
AU2012229123B2 (en) 2017-02-02
WO2012125828A2 (en) 2012-09-20
US20150252440A1 (en) 2015-09-10
JP2014514278A (ja) 2014-06-19
AU2017202786A1 (en) 2017-05-18
AU2012229123A1 (en) 2013-10-03
EP2685988A2 (en) 2014-01-22
EP2685988A4 (en) 2014-08-20
US20130004482A1 (en) 2013-01-03
CA2830240A1 (en) 2012-09-20
IL228449A (en) 2017-10-31
WO2012125828A3 (en) 2012-11-08
AU2012229123A8 (en) 2013-11-07
US9066963B2 (en) 2015-06-30
WO2012125828A8 (en) 2013-11-28
IL228449A0 (en) 2013-12-31
JP2016130256A (ja) 2016-07-21

Similar Documents

Publication Publication Date Title
US20230272476A1 (en) Nano46 genes and methods to predict breast cancer outcome
JP2016130256A (ja) アントラサイクリン療法を用いて乳癌を処置する方法
JP6144695B2 (ja) タキサン療法を用いて乳癌を処置する方法
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
JP6140202B2 (ja) 乳癌の予後を予測するための遺伝子発現プロフィール
US20150072021A1 (en) Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
US20140154681A1 (en) Methods to Predict Breast Cancer Outcome
US20160115551A1 (en) Methods to predict risk of recurrence in node-positive early breast cancer
US20160160293A1 (en) Breast cancer treatment with taxane therapy
CN110431238A (zh) cfRNA的液体活检
WO2019215394A1 (en) Arpp19 as biomarker for haematological cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160707

R150 Certificate of patent or registration of utility model

Ref document number: 5971769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees